Single and combined use of neutrophil–lymphocyte ratio, platelet–lymphocyte ratio and carcinoembryonic antigen in diagnosing gastric cancer

Wu, Yangyang; Jiang, Maoqin; Qin, Yuanyuan; Lin, Faquan; Lai, Ming‐Yu

doi:10.1016/j.cca.2018.02.027

Cited by 39 publications

(41 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After covariate adjustment, only the NLR was independently associated with worse OS and DFS. Our findings are in accordance with previous reports in patients with solid tumors, including gastric cancer [11,[17][18][19][20]. Moreover, the majority of these studies assessing the role of NLR and PLR as prognostic biomarkers have been conducted in Asian populations, and almost no data from Latin-American countries are available.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

The Neutrophil-Lymphocyte Ratio Is an Independent Prognostic Factor for Overall Survival in Hispanic Patients with Gastric Adenocarcinoma

Ramos-Esquivel

Cordero-García

Brenes-Redondo

et al. 2018

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

“…The neutrophil-lymphocyte ratio (NLR) and the plateletlymphocyte ratio (PLR) have been recently identified as prognostic factors in patients with solid tumors, including gastric cancer [10,11]. However, the prognostic role of these biomarkers in patients with gastric adenocarcinoma from Hispanic origin is largely unknown.…”

Section: Introductionmentioning

confidence: 99%

The Neutrophil-Lymphocyte Ratio Is an Independent Prognostic Factor for Overall Survival in Hispanic Patients with Gastric Adenocarcinoma

Ramos-Esquivel

Cordero-García

Brenes-Redondo

et al. 2018

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

“…In this study, the median value of CEA in the GC group was 2.74 (1.685-5.62) ng/ ml, which was higher than the 1.525 (1.09-2.385) ng/ml in the benign control, and the difference was statistically significant. When we used the clinically recommended 3.4 ng/ml as the cut-off value, the sensitivity was 0.409, the specificity was 0.942, and the AUC was 0.676, which are consistent with previous research [23,24]. Therefore, we believe that the level of CEA can help diagnose GC.…”

Section: Discussionsupporting

confidence: 88%

The significance of preoperative serum carcinoembryonic antigen levels in the prediction of lymph node metastasis and prognosis in locally advanced gastric cancer: a retrospective analysis

et al. 2020

View full text Add to dashboard Cite

Background: In this study, we aimed to investigate the preoperative serum carcinoembryonic antigen (CEA) in the diagnosis of positive lymph node metastasis (LNM), and to evaluated the relationship between CEA and survival in patients with locally advanced gastric cancer (LAGC). Methods: The significance of the preoperative serum CEA level for the diagnose of LAGC and prediction of LNM was determined using the receiver operating characteristic (ROC) curve. The areas under the ROC of CEA were compared with those of other tumor markers or imaging examination including CT and MRI. Logistic regression was utilized to identify the risk factors predicting positive LNM. Independent prognosis factors were evaluated using univariate and multivariate COX regression analyses. Results:The ROC curves showed that the AUCs of CEA, CA199, and CA125 for diagnosing LAGC were 0.727, 0.594, and 0.566. When used to predict LNM, the AUC of CEA, CA199 and CA125 were 0.696, 0.531, and 0.588. Logistic regression analysis demonstrated that preoperative serum CEA were significantly associated with positive LNM. On combining imaging examination with CEA, the sensitivity and specificity were 85.3 and 79.4%, respectively, with the AUC equal to 0.853. The combination of CEA and imaging examination preformed the highest levels of AUC and sensitivity for diagnosing LNM, which is significantly higher than using either of them alone. Although patients with abnormal CEA have a poor prognosis, two models of multivariate analysis showed that CEA was not the independent prognosis factor for survival.Conclusions: CEA can be used to diagnose gastric cancer and determine whether it has LNM. Moreover, combined with CEA could improve the diagnostic sensitivity of imaging examination for lymph node involvement.

show abstract

“…Platelet is a key factor in tumor growth, metastasis and cancer-related thrombosis (6), such as endometrial cancer, gastric cancer, pancreatic cancer, etc. (7)(8)(9). Recent studies have found that platelet-related markers, such as the ratio of platelets to lymphocytes, are more significant prognostic factors in patients with bladder cancer (10).…”

Section: Introductionmentioning

confidence: 99%

The prognostic impact of preoperative platelet distribution width-to-platelet count ratio in patients with bladder cancer

Wu¹,

Xu²,

Gao³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Preoperative platelet distribution width-to-platelet count ratio (PDW/PLT) has been discussed about its prognostic value in several malignancies, whereas its role in bladder cancer remains unclear. In this study, we attempt to investigate the relationship between the PDW/PLT and the prognosis of patients with bladder cancer.Patients and Methods The clinical data of 115 cases of bladder cancer treated in urology department of Nantong tumor hospital from January 2009 to August 2014 were analyzed retrospectively. The best critical value of PDW/PLT was 0.09965 determined by ROC curve. The patients were divided into low PDW/PLT group and high PDW/PLT group. After 5 years of follow-up, survival was observed, and the clinicopathological data of patients were statistically analyzed. Kaplan Meier method and log rank test were used for single factor survival analysis, and Cox regression analysis was used for multiple factors survival analysis.Results The age of patients in low PDW/PLT group was significantly lower than that in high PDW/PLT group (P=0.008). There was no significant difference between the two groups in gender, TNM stage, grade, lymph node metastasis, distant metastasis, operation method, history of hypertension, history of diabetes, and other operation history (P>0.05). All patients were followed up for 5 years. 89 patients survived, the survival rate was 77.4%, 26 patients died, the mortality rate was 22.6%. There were 94 cases (81.7%) in low PDW/PLT group and 21 cases (18.3%) in high PDW/PLT group. The tumor progression rates of low PDW/PLT group and high PDW/PLT group were 57.4% (54/94) and 71.4% (15/21) respectively. The median PFS was 85 months and 71 months respectively. There was no significant difference between the two groups (P>0.05). Single factor analysis showed that TNM stage, grade, lymph node metastasis, PDW/PLT were the factors affecting OS (P<0.05). The results of Cox multivariate analysis showed that PDW/PLT was an independent risk factor for tumor progression (P＜0.05). The increase of PDW/PLT can significantly reduce OS and PFS in patients with bladder cancer.Conclusions PDW/PLT is an independent prognostic factor in patients with bladder cancer, and it is related to the clinicopathological characteristics. It has a certain value in evaluating the prognosis of patients with bladder cancer.

show abstract

Single and combined use of neutrophil–lymphocyte ratio, platelet–lymphocyte ratio and carcinoembryonic antigen in diagnosing gastric cancer

Cited by 39 publications

References 36 publications

The Neutrophil-Lymphocyte Ratio Is an Independent Prognostic Factor for Overall Survival in Hispanic Patients with Gastric Adenocarcinoma

The Neutrophil-Lymphocyte Ratio Is an Independent Prognostic Factor for Overall Survival in Hispanic Patients with Gastric Adenocarcinoma

The significance of preoperative serum carcinoembryonic antigen levels in the prediction of lymph node metastasis and prognosis in locally advanced gastric cancer: a retrospective analysis

The prognostic impact of preoperative platelet distribution width-to-platelet count ratio in patients with bladder cancer

Contact Info

Product

Resources

About